Zobrazeno 1 - 10
of 10
pro vyhledávání: ''
Publikováno v:
Expert Review of Anticancer Therapy. 21:365-372
Introduction: There are 400,000 new cases of Renal Cell Carcinoma (RCC) and 175,000 deaths worldwide every year. Currently available frontline therapies to treat RCC have less toxicity than previou...
Publikováno v:
Expert Review of Anticancer Therapy. 20:1075-1081
The treatment of chronic myeloid leukemia (CML) has been drastically changed by the approval of tyrosine kinase inhibitors (TKIs). CML is now managed as a chronic disease requiring both long-term treatment and close molecular monitoring in the majori
Autor:
Almuth Maria Anni Merz, Sarah A. Holstein, Jens Hillengass, Philip L. McCarthy, Maximilian Merz
Publikováno v:
Expert Review of Anticancer Therapy. 19:889-898
Introduction: Maintenance therapy after autologous transplantation is a standard of care in newly diagnosed myeloma. However, there is no universal answer to the question of which maintenance strategy should be pursued after ASCT? Areas covered: We c
Publikováno v:
Expert Review of Anticancer Therapy. 19:273-286
INTRODUCTION Mutations of the FLT3 gene are among most common genetic abnormalities occurring in acute myeloid leukemia (AML) and are associated with dismal prognosis. Tremendous effort has been devoted to developing clinically effective FLT3 inhibit
Autor:
Francesca Bergamo, Rossana Intini, Vittorina Zagonel, Marta Schirripa, Alessandra Ferro, Heinz-Josef Lenz, Alberto Puccini, Fotios Loupakis, Francesca Battaglin, Sara Lonardi
Publikováno v:
Expert Rev Anticancer Ther
Introduction: Angiogenesis is a complex process regulated by several pro- and anti-angiogenic factors, thus the loss of its fine equilibrium plays a key role in colorectal cancer (CRC) development and progression. Therapeutic agents targeting VEGF/VE
Autor:
Elisabetta Setola, Jonathan Noujaim, Robin L. Jones, Sant P. Chawla, Charlotte Benson, Emanuela Palmerini
Publikováno v:
Expert Review of Anticancer Therapy. 17:717-723
Introduction: The heterogeneity of soft tissue sarcomas (STS) presents a formidable management challenge. Consequently, one of the main research goals is to define specific tailored therapy for each histological subtype and to develop a more personal
Publikováno v:
Expert Review of Anticancer Therapy. 17:567-576
Sorafenib is the standard of care for patients with advanced hepatocellular carcinoma (HCC) and well preserved liver function. However, until recent approval of regorafenib by the Food and Drug Administration (FDA), no effective therapeutic options w
Publikováno v:
Expert Review of Anticancer Therapy. 17:257-270
Metastatic/advanced soft tissue sarcoma has a poor prognosis conventionally, treatment options have been limited. In recent years, this area has been a rich ground for research with many new drugs being approved and several more in the pipeline. With
Autor:
Ignacio Romero, Gabriella Ferrandina, Nicoletta Colombo, Anne Claire Hardy-Bessard, Christian Marth
Publikováno v:
Expert Review of Anticancer Therapy. 16:11-19
Introduction: As most patients with ovarian cancer experience multiple remissions and relapses, oncologists must prepare ahead for long-term treatment. While platinum-based regimens are standard of care for platinum-sensitive recurrence, there are ci
Publikováno v:
Expert Review of Anticancer Therapy. 16:57-70
Ovarian cancer is the most aggressive gynecological cancer. One reason for the low 5-year survival rate of under 40% is that ovarian tumors usually acquire resistance to the platinum-based compounds used to treat them. Resistance to one such compound